Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) announced detailed results from the QWINT-5 phase 3 trial evaluating once-weekly insulin efsitora alfa compared to once-daily insulin degludec in adults with type 1 diabetes. The study met its primary endpoint of non-inferior A1C reduction at week 26, with efsitora reducing A1C by 0.53% compared to 0.59% for insulin degludec. Key secondary endpoints showed similar time in range and rates of nocturnal hypoglycemic events between the two treatments.

However, efsitora showed higher rates of severe hypoglycemic events (0.14 vs 0.04 per patient-year) compared to insulin degludec, with 64% of these events occurring in the first 12 weeks of treatment. The results highlight the potential of efsitora to offer a once-weekly basal insulin option for type 1 diabetes patients, while also emphasizing the need for careful management of hypoglycemia risk.

Eli Lilly and Company (NYSE: LLY) has announced promising results from the QWINT-2 phase 3 trial of once-weekly insulin efsitora alfa compared to once-daily insulin degludec in adults with type 2 diabetes. The study, published in The New England Journal of Medicine and presented at EASD 2024, showed that efsitora met its primary endpoint of non-inferior A1C reduction. Key findings include:

- Efsitora reduced A1C by 1.34% vs. 1.26% for insulin degludec
- Participants achieved 45 minutes more time in range per day with efsitora
- No severe hypoglycemic events were reported with efsitora
- Efsitora demonstrated a safety profile similar to daily insulins

These results suggest efsitora could offer a convenient once-weekly option for type 2 diabetes patients, potentially improving treatment adherence while providing comparable outcomes to daily insulins.

Eli Lilly and Company (NYSE: LLY) has appointed Lucas Montarce as executive vice president and chief financial officer (CFO), effective immediately. Montarce, who joined Lilly in 2001, has held various finance leadership roles within the company, including group vice president, corporate controller, and CFO of Lilly Research Laboratories. He most recently served as Lilly president and general manager for the Spain, Portugal and Greece hub.

Montarce holds a bachelor's degree in business accounting from Catholic University (Argentina) and an MBA from the Center for Macroeconomic Studies of Argentina. CEO David A. Ricks expressed confidence in Montarce's abilities, citing his drive, curiosity, and integrity. Montarce stated his commitment to building on Lilly's strong financial foundation and driving continued success as the company expands its global footprint.

Eli Lilly has announced positive topline results from two phase 3 clinical trials, QWINT-1 and QWINT-3, evaluating once weekly insulin efsitora alfa in adults with type 2 diabetes. The trials showed that efsitora was non-inferior to daily basal insulins in reducing A1C levels.

QWINT-1 studied insulin-naïve patients, using a novel fixed-dose regimen with four doses administered via a single-use autoinjector. QWINT-3 focused on patients switching from daily basal insulin. Both trials met their primary endpoints, demonstrating similar A1C reductions to daily insulins glargine and degludec, respectively.

Efsitora showed a comparable safety profile to daily basal insulins, with QWINT-1 reporting approximately 40% lower rates of severe or clinically significant hypoglycemic events compared to insulin glargine.

Eli Lilly and Company (NYSE: LLY) has partnered with EVA Pharma to expand access to baricitinib in 49 low- to middle-income African countries. This collaboration aims to reach an estimated 20,000 people by 2030, aligning with Lilly's 30x30 initiative to improve healthcare access for 30 million people in resource- settings annually by 2030.

EVA Pharma will manufacture and supply baricitinib locally, with sales expected to begin by 2026. This agreement marks Lilly's first voluntary licensing agreement, providing manufacturing know-how to EVA Pharma. The collaboration builds on their existing partnership to expand access to affordable insulin in 56 countries, as announced in 2022.

Eli Lilly (NYSE: LLY) has announced the release of Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials for self-pay patients with obesity. This expansion aims to meet high demand and broaden access to the medication. The vials are priced at least 50% less than other incretin medicines for obesity. Available through LillyDirect®'s self-pay channel, the 2.5 mg four-week supply costs $399, while the 5 mg dose is $549.

Zepbound, which activates both GIP and GLP-1 hormone receptors, achieved an average of 15% weight loss over 72 weeks in clinical trials. The single-dose vials are intended for adults with obesity or overweight individuals with weight-related medical problems. Lilly emphasizes the importance of using Zepbound with a reduced-calorie diet and increased physical activity.

Eli Lilly and Company (NYSE: LLY) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024. Jacob Van Naarden, executive vice president and president of Lilly Oncology, will engage in a fireside chat at 7:45 a.m. Eastern time.

Investors and interested parties can access a live audio webcast of the presentation through Lilly's Investor website. The webcast will be available in the 'Webcasts & Presentations' section at https://investor.lilly.com/webcasts-and-presentations. For those unable to attend live, a replay of the presentation will be accessible on the same website for approximately 90 days following the event.

Eli Lilly's tirzepatide showed remarkable results in a 176-week SURMOUNT-1 Phase 3 study for long-term weight management and diabetes prevention. The drug reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. Participants on the 15 mg dose experienced an average 22.9% decrease in body weight compared to 2.1% for placebo.

The study involved 1,032 adults with pre-diabetes and obesity or overweight. Tirzepatide, a GIP and GLP-1 receptor agonist, demonstrated sustained weight loss and significant reduction in diabetes risk throughout the treatment period. The safety profile was consistent with previous studies, with gastrointestinal-related adverse events being most common.

Eli Lilly and Company (NYSE: LLY) has announced the retirement of Marschall S. Runge, M.D., Ph.D. from its Board of Directors, effective Aug. 31, 2024. Dr. Runge, who has served on Lilly's board since 2013, is also retiring from his roles as CEO of Michigan Medicine, executive vice president for medical affairs at the University of Michigan, and dean of the Medical School on June 30, 2025. He will remain on the Medical School faculty as a professor.

During his tenure, Dr. Runge served on the board's Science and Technology Committee and Ethics and Compliance Committee, bringing decades of experience as a physician, scientist, and expert in health care faculty systems, biomedical research, clinical trial design, and patient safety. His research-driven perspective has been particularly valuable in the areas of diabetes and obesity treatments.